This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Investors will hope shares in mixer maker Fevertree Drinks will regain their fizz as it begins to step up its overseas expansion. The Aim-listed firm’s share price has surged 101pc in the last year but the market darling’s momentum was slowed in May when it failed to deliver its customary earnings upgrade. City analysts warned that investors may have to brace for a transition year as it tries to tap the huge US market to maintain its explosive growth.
KAZ RDS.B RDS.A AAL BATS RDSB 4162 RDSA JMPLF FQVTF FEVR AAUKF RYDBF JMPLY RYDAF NGLOY
VANCOUVER, British Columbia, July 19, 2018 (GLOBE NEWSWIRE) -- Peregrine Diamonds Ltd. (TSX:PGD) (“Peregrine” or “the Company”) is pleased to announce that it has entered into an arrangement agreement (the “Arrangement Agreement”) with De Beers Canada Inc. (“De Beers”) under which De Beers will acquire all of the Company’s outstanding common shares for $0.24 per share in cash or a total equity value of approximately $107 million pursuant to a plan of arrangement (the “Arrangement”) under the Canada Business Corporations Act.
PGD AAUKF PGDIF MALRY MDM AAL MALRF MIN NGLOY MPVD
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BLT LUNMF BHPBF FCX AAL LUNCF LUN NSU BHP AAUKF BBL FQVLF BHP FQM BHPLF NGLOY
LONDON (Reuters) - A U.S. demand for documents related to Glencore’s (GLEN.L) assets in Democratic Republic of Congo (DRC) as part of a corruption probe has rattled investors and is likely to weigh on the miner’s performance until there is more clarity on the case.
RTPPF RIO RIO AAUKF RIO RTNTF AAL NGLOY
A U.S. demand for documents related to Glencore's assets in Democratic Republic of Congo (DRC) as part of a corruption probe has rattled investors and is likely to weigh on the miner's performance until there is more clarity on the case.
RTPPF RIO RIO AAUKF RIO RTNTF AAL NGLOY
VANCOUVER, British Columbia, July 09, 2018 (GLOBE NEWSWIRE) -- Group Ten Metals Inc. (TSX-V:PGE) (US OTC:PGEZF) (FSE:5D32) (the “Company” or “Group Ten”) is pleased to provide an update on progress at its flagship Stillwater West PGE-Ni-Cu-Co project, including 2018 exploration plans and the acquisition of new claims which expand the Company’s land position in the Stillwater district by over 23% to approximately 54 square kilometers.
DCGCF PGE PGEZF AAUKF NCPCF AAL NGLOY
VANCOUVER, British Columbia, July 09, 2018 (GLOBE NEWSWIRE) -- Lumina Gold Corp. (TSX-V:LUM) (OTC:LUMAF) (the “Company” or “Lumina”) is pleased to announce that its board of directors (the “Lumina Board”) has unanimously approved a strategic reorganization of its business (the “Arrangement”). Pursuant to the Arrangement, all of Lumina’s concessions and properties, with the exception of the Cangrejos Gold-Copper Project will be spun out to Lumina shareholders through a newly incorporated company, Luminex Resources Corp.
AAUKF FQVLF AAL LUMAF FQM NGLOY
LONDON, July 6 (Reuters) - Private equity-backed Chilean miner Mantos Copper is looking to find a buyer to help finance the expansion of mines it bought from Anglo American in 2015, it said.
RTPPF RIO RIO SCGLF AAUKF RIO RTNTF SCGLY AAL GLE NGLOY
New Delhi : Mining mogul Anil Agarwal’s plan to delist Vedanta Resources from the London Stock Exchange will not immediately affect the company’s credit profile or rating, Moody’s Investors Service said on Thursday.
VED AAUKF LNSTY AAL NGLOY
LONDON: Glencore Plc will buy back as much as US$1bil of its shares, a move that may soothe investor concerns after the world’s top commodity trader was hit by a US Department of Justice probe earlier this week.
BLT BHP AAUKF BHPBF BBL AAL BHP BHPLF NGLOY
Anglo American and Origin will be taking part in the annual hackathon Unearthed, designed to connect industries and budding innovators to partner and deliver technology solutions to the mining and resources industries.
AAUKF AAL NGLOY
Hopes of a gush of bumper shareholder returns at mid-cap oil producers Tullow Oil and EnQuest boosted their shares towards the top of London’s leaderboard before a sudden crude price dip dampened their gains.
VED AAUKF TLW AAL NGLOY
Mining mogul Anil Agarwal's plan to delist Vedanta Resources from the London Stock Exchange will not immediately affect the company's credit profile or rating, Moody's Investors Service said today. "This is based on our expectation that Volcan (holding company) will not extract incremental cash from Vedanta to provide additional liquidity for itself," Moody's said.
VED AAUKF LNSTY AAL NGLOY VEDL
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET